Abstract
Aims This prospective study aimed to determine the proportions of therapeutic inertia when treatment targets not achieved in adults T2D at three public health clinics in Malaysia.
Methods The index prescriptions were those when the annual blood tests were reviewed. Prescriptions were verified and classified as 1) no change, 2) stepping up and 3) stepping down. Multivariable logistic regression and sensitive analyses were conducted.
Results At follow-up, 552 participants were available for the assessment of therapeutic inertia (78.9% response rate). The mean (SD) age and diabetes duration were 60.0 (9.9) years and 5.0 (6.0) years, respectively. High therapeutic inertia were observed in oral anti-diabetic (61-72%), anti-hypertensive (34-65%) and lipid-lowering therapies (56-77%), and lesser in insulin (34-52%). Insulin therapeutic inertia was more likely among those with shorter diabetes duration (adjusted OR 0.9, 95% CI 0.87, 0.98). Those who did not achieve treatment targets were less likely to experience therapeutic inertia: HbA1c ≥ 7.0%: adjusted OR 0.10 (0.04, 0.24); BP ≥ 140/90 mmHg: 0.28 (0.16, 0.50); LDL-cholesterol ≥ 2.6 mmol/L: 0.37 (0.22, 0.64).
Conclusions Although therapeutic intensifications were more likely in the present of non-achieved treatment targets but the proportions of therapeutic inertia were high.
Trial registration NCT02730754 https://clinicaltrials.gov/ct2/show/NCT02730754
Highlights
Probably the first study in Malaysia or Asian countries
Assessing three main therapeutic inertia among T2D at primary diabetes care
Proportions of therapeutic inertia were high
Therapeutic inertia was unlikely in non-achieved treatment targets
Possible causes of therapeutic inertia require identification and rectification
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02730754
Funding Statement
This work was partly supported by the Ministry of Higher Education Malaysia (grant numbers KPT(BS)730928075371, 2013) and Universiti Putra Malaysia?s journal publication awards (award numbers UPM/TNCPI/RMC/5.1.17/F5(16)). The funding bodies had no role in the design of the study or in the collection, analysis, or interpretation of data or in writing the manuscript.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Not Applicable
Data Availability
Data will be made available upon request.
